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Summary In the present investigation the antiprolifer-
ative activity of thirteen derivatives of betulinic acid and
betulin was tested against five different tumor cell lines.
The toxicity against normal human fibroblasts
(WWO70327) and the mode of cell death on HT-29
(colon cancer) as well as caspase activity induced by the
most active compounds, 9 (3-O-chloroacetylbetulinic
acid) and 15 (28-O-chloroacetylbetulin) were determined.
Investigated derivatives exerted a dose dependent anti-
proliferative action at micromolar concentrations toward
target tumor cell lines. Treatment of HT-29 cells for 24 h
with 9 and 15 induced apoptosis, as observed by dye
exclusion test (trypan blue) and confirmed by the
appearance of a typical ladder pattern in the DNA
fragmentation assay.
Keywords Betulinic acid . Betulin . Natural products .
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Introduction
Pentacyclic lupane type of triterpenoids represents one of
the very important classes of natural products. The
compounds of this class which includes betulin and
betulinic acid, were found to show significant antitumor
activity on a broad panel of cancers [1–3]. Betulinic acid
was found to cause cancer cell death by induction of
apoptosis involving caspases. Moreover it was demonstrat-
ed that betulinic acid was well tolerated in mice up to
500 mg/kg with no toxic effects [4]. The induction of
apoptosis is through the induction of changes in mitochon-
drial membrane potential, production of reactive oxygen
species, and permeability of transition pore openings [2].
These processes lead to the release of mitochondrial
apoptogenic factors, activation of caspases, and DNA
fragmentation [5–7]. It was observed that betulinic acid
inhibited the in vitro activity of aminopeptidase N [8], an
endogenous angiogenic factor, but could not inhibit the
enzyme in vivo even though it inhibits mitochondrial
function in endothelial cells [9]. Betulinic acid, by an
antioxidant mechanism tends to protect congenital melano-
cyte naevi cells from UV-C-induced DNA strand breakage
independent of p53 and p21 [10]. Betulinic acid induces
weak inhibitory effects against topoisomerase I and IIa, but
does not stabilize the topoisomerase IIa–DNA complex
[11]. Betulinic acid is active in vivo against TPA-induced
tumors [12, 13]. Betulinic acid and betulin were also found
to show antimalarial [14, 15], anti-inflammatory [16, 17],
anti-HIV activities [18].
Currently, the development of new anticancer agents is
focused on discovering diverse compounds with either
novel structures or a new mechanism(s) of action. Discov-
ery of novel plant-derived natural products as potential new
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lead compounds for anticancer agents as well as the
modification of these new lead compounds is continuing
goals of our laboratory. Suitable structural modification of
the initial lead structures may provide analogs with greatly
enhanced activity. In the present study, we investigated the
antiproliferative activity of 13 derivatives of betulinic acid
and betulin (Fig. 1). The synthesis of these derivatives was
recently reported by our group [19]. The structure in vitro
anticancer activity relationship, the mode of action on five
tumor cell lines and toxicity to normal human fibroblasts
was investigated. Furthermore, the mode of cell death
caused by the most active derivatives, as well as caspase 2,
3, 8 and 9 activities were determined.
Materials and methods
Chemistry
Compounds 3–9 were synthesized from betulinic acid and
compounds 10–15 were synthesized from betulin [19]. In
the panel of betulinic acid derivatives compounds 3, 8 and
9 were prepared using corresponding anhydrides in lab
scale single mode microwave whereas compounds 5–7
were produced by conversion of 3 into acid chloride and
reacting with corresponding alcohols in excess. Derivatives
10–15 are obtained by treating betulin with respective
anhydrides in lab scale single mode microwave. Structures
of all obtained amides were confirmed by standard
spectroscopic techniques (1H and 13C NMR, MS) and
reported [19].
Reagents
Betulinic acid (1) and betulin (2) were obtained as a kind
gift from BioSolutions Halle GmbH (Halle, Germany).
Solvents were obtained commercially and used without
further purification. Synthesis under pressure was per-
formed in a lab scale single mode microwave (CEM Corp,
USA). Stock solutions of investigated compounds were
prepared in a dimethyl sulfoxide (DMSO) at concentrations
of 20 mM and afterwards they were diluted with complete
nutrient medium (RPMI-1640 with L-glutamine(PAA Labs,
Pasching, Austria)) containing 10% heat inactivated fetal
bovine serum (FBS) (Biochrom AG, Berlin, Germany) and
1% Penicillin/Streptomycin (100X) (PAA Labs, Pasching,
Austria).
Cell culture
The cell lines 518A2, human melanoma, A549, lung
cancer, FaDu, head and neck cancer, HT-29, colon cancer,
MCF-7, breast cancer and WWO70327, human fibroblasts
were included in this study. All these cell lines were
kindly provided by Dr Thomas Mueller, Department of
Hematology/Oncology, Martin Luther University of Halle-
Wittenberg, Halle (Saale), Germany. Cultures were main-
tained as monolayers in RPMI 1640 supplemented with
10% heat inactivated fetal bovine serum and 1% penicil-
lin/streptomycin at 37◦ C in a humidified atmosphere with
5% CO2.
Cytotoxicity assay
The cytotoxic activities of all the compounds were
evaluated using the sulforhodamine-B (SRB) (Sigma
Aldrich) microculture colorimetric assay [20]. In short,
exponentially growing cells were seeded into 96 well plates
on day 0 at the appropriate cell densities to prevent
confluence of the cells during the period of experiment.
After 24 h, the cells were treated with serial dilutions of the
compounds (0–100µM) for 96 h. The percentages of
surviving cells relative to untreated controls were deter-
mined 96 h after the beginning of drug exposure. After 96 h
treatment, the supernatant medium from the 96 well plates
was thrown away and the cells were fixed with 10% TCA.
For a thorough fixation plates are now allowed to stand at
4 ◦C for at least 2 h. After fixation the cells are washed in a
strip washer. The washing is done four times with water
using alternate dispensing and aspiration procedures. The
plates are then dyed with 100 µL of 0.4% SRB for about
45 min. After dying the plates are again washed to remove
the dye with 1% acetic acid and allowed to air dry
overnight. 100 µL of 10 mM Tris base solution was added
to each well of the plate the next day and absorbance wasFig. 1 Investigated betulinic acid (I) and betulin (II) derivatives
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measured at 570 nm using a 96 well plate reader (Tecan
Spectra, Crailsheim, Germany). The IC50 and IC90 values,
defined as the concentrations of the compound at which 50
and 90% cell inhibition is observed, was estimated from the
semi-logarithmic dose-response curves.
Apoptosis tests
Trypan blue—dye exclusion test
Apoptotic cell death was analyzed by trypan blue dye
(Sigma Aldrich, Germany) on HT-29 cell line. The cell
culture flasks with 70 to 80% confluence were treated with
IC90 doses of 9 and 15 for 24 h. The supernatant medium
with floating cells was collected after treatment and
centrifuged to collect the dead and apoptotic cells. The cell
pellet was re-suspended in serum free media. Equal
amounts of cell suspension and trypan blue were mixed
and this was analyzed under a microscope. The cells, which
were viable, excluded the dye and were colorless and the
ones whose cell membrane was destroyed were turning into
blue.
DNA fragmentation assay
Determination of apoptotic cell death was further confirmed
by DNA laddering technique using gel electrophoresis.
Briefly, HT-29 cells were treated with respective IC90 doses
of 9 and 15 for 24 h respectively. Floating cells induced by
drug exposure were collected, washed with PBS and lysed
with lysis buffer (100 mM Tris-HCL Ph 8.0; 20 mM
EDTA; 0.8% SDS; all from Sigma Aldrich). Then, cells
were treated with RNAse A at 37°C for 2 h and proteinase
K at 50°C (both from Roche Diagnostics chemical
company, Mannheim, Germany). DNA laddering was
observed by running the samples on 2% agarose gel
followed by ethidium bromide (Sigma Aldrich) staining.
Caspase 2, 3, 8 and 9 enzyme activity assay
Activity of caspases 2, 3, 8 and 9 was measured using the
caspase substrate cleavage assay. After exposure to equi-
toxic IC90 concentrations of 1, 9 and 15, cells were sampled
2, 6 and 24 h for cleavage of caspases. To summarize,
adherent cells were washed with cold PBS, collected with a
cell scraper, and suspended in cell lyses buffer (50 mM
Hepes pH 7.4, 1% Triton X100, all from Sigma-Aldrich).
After incubation for 10 min on ice and centrifugation,
protein concentrations of the supernatants were measured
according to method of Bradford (Bio-Rad Laboratories).
Samples (50μg protein extract respectively) were incubated
on a microplate at 37°C overnight in reaction buffer
(50 mM Hepes pH 7.4, 0.1% CHAPS, 5 mM EGTA, 5%
glycerol) containing 10 mM DTT (all from Sigma-Aldrich)
and a specific substrate of caspases (2, Ac-VDVAD-pNA;
3, Ac-DEVD-pNA; 8, Ac-IETD-pNA; 9, Ac-LEHD-pNA,
Axxora, Loerrach, Germany). Extinction of released p-
nitroaniline was measured at 405 nm (Tecan Spectra,
Crailsheim, Germany) and activity of caspases 2, 3, 8 and
9 was evaluated by OD ratio of treated/untreated samples
[21].
Results
In vitro antitumoral studies
The in vitro cytotoxic activity of the derivatives of betulinic
acid and betulin was studied on five different tumor cell
lines, 518A2 (melanoma), A549 (lung tumor), FaDu (head
and neck), HT-29 (colon), and MCF-7 (breast cancer) by
sulforhodmine B colorimetric assay method. The com-
pounds showed dose dependent antitumoral activity against
investigated cell lines (Fig. 2). The IC50 values of each
compound on these cell lines are given in Table 1.
Our preliminary investigation showed that betulinic acid
(1) and betulin (2) derivatives are potential lead compounds
for new antitumor agents. Some of the derivatives showed
increased cytotoxic activity judged against starting com-
pounds. No cytotoxic activity was observed for derivatives
made from betulinic acid viz. 6 and 7 within 0–100µM
concentration range. Moderate activity was observed in
case of compound 4 and 8 on the investigated cell lines.
Compound 5 showed activity at higher concentrations. On
the other hand the derivative 9 showed a substantially better
activity than the parent compound. Similarly, among the
derivatives synthesized from betulin, 12, 13 and 11 were
moderately active and 10 showed no activity within
investigated concentration range except in breast cancer
cell line (MCF-7), whereas the compound 14 showed
moderate activity. The derivative of betulin, 15 was found
to exhibit a moderate to good activity in almost all the cell
lines. Based on the results obtained, we could summarize
that derivatization of the hydroxyl groups of triterpenes by
chloro acetic anhydride increases cytotoxic activity. Mod-
ification of C-3 of betulinic acid with acetic anhydride
resulted in a slight increase of potency than betulinic acid.
Esterification of C-28 carboxylic acid of 3, acetyl betulinic
acid, either with short or long chain alkyl groups led to
either loss or a decreased cytotoxic activity in comparison
to the parent compound. Even substitution with 1, 6-
chlorohexyl group has not yielded a better result. The most
active derivative 9, 3-O-chloroacetylbetulinic acid, was
found to show high cytotoxic activity against broad
spectrum of tumors from different histogenetic origin.
Moreover compound 9 was 2–4 times more cytotoxic than
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Fig. 2 Survival of tumor cells and non-tumor cells (WWO70327), SRB test, after 96 h of continuous action of applied concentrations of 9 (∎) and 15 (●)
Compound 518A2 A549 FADU HT-29 MCF-7
1 8.13±0.04 11.1±1.83 10.19±0.09 13.93±0.46 12.27±0.19
3 4.65±0.66 6.73±2.09 12.24±0.82 16.14±1.20 11.06±0.87
4 28.75±2.38 20.63±0.95 20.33±0.83 30.72±2.79 24.39±0.51
5 82.90±5.98 45.17±18.70 25.52±0.566 79.78±1.19 82.56±2.38
6 >100 >100 >100 >100 >100
7 >100 >100 >100 >100 >100
8 28.92±5.21 14.69±3.27 20.29±1.47 22.10±1.30 28.76±3.99
9 8.44±0.38 3.05±0.46 5.19±0.69 3.6±0.28 7.92±1.42
10 >100 >100 >100 >100 55.64±2.23
11 40.80±2.78 73.42±2.00 62.46±0.94 52.59±4.56 40.78±0.88
12 38.72±2.00 58.08±19.32 41.73±3.49 25.68±2.51 35.32±1.51
13 65.54±2.21 70.33±4.54 43.61±11.62 41.66±1.80 20.21±1.36
14 15.84±0.66 14.37±2.20 13.95±6.31 10.96±0.87 11.38±0.93
15 9.91 ±0.16 11.00±0.70 19.47±1.61 27.63±1.88 8.14±5.41
Table 1 IC50 [μmol] of the
investigated betulin and
betulinic acid derivatives
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betulinic acid on FaDu, A549 and HT-29 (colon cancer)
cell lines. The compound 9 has shown a very high
magnitude of cytotoxicity on A549, lung tumor cell line.
Selectivity
Furthermore, the most active derivatives 9 and 15 were
screened for their selectivity towards tumor cells. To
assess selectivity, the active compounds were tested on
human fibroblasts (WWO70327). The IC50 of betulinic
acid, 1, was found to be 20 ± 0.20µM and for 9 and 15,
10 ± 1.87 and 15 ± 3.50µM respectively. Interestingly it
was observed that the compounds 9 and 15 were less toxic
on these cells than on the investigated tumor cell lines,
except for FaDu and HT-29 cell lines with compound 15.
It was observed that 15 showed a higher selectivity than
betulinic acid towards breast cancer (MCF-7) cell line.
Similarly, for compound 9 was found to be nearly 2 fold
more selective than betulinic acid in A549, lung tumor cell
line and HT-29, colon cancer cell line. Furthermore,
compound 9 was found to be 3.3 times more selective to
lung tumor cell line and 2.9 times more selective to colon
cancer cell line than to human fibroblast cells. In addition,
the human fibroblasts (WWO70327) showed better tolerance
to compound 9 in comparison with betulinic acid in most
cases.
Compounds 9 and 15 induce apoptosis
To test whether 9 and 15 induced cell death was mediated
by apoptosis, floating cells from HT-29 after 24 h treatment
with the IC90 concentrations were collected and analysed
by the DNA laddering technique (Fig. 3). In the colon
cancer cell line with both compounds, occurrence of typical
DNA ladders was observed. Furthermore, programmed cell
death was also observed by trypan blue exclusion test, in
which floating cells showed the ability to exclude the blue
dye indicating that 9 and 15 cause cell death by the
induction of apoptosis.
Effect of 1, 9 and 15 on the kinetics of caspases 2, 3, 8
and 9 activities
To gain insight into the molecular changes of the new
derivatives-induced apoptosis, it was analyzed whether
caspases are involved as effectors in the induced cell death.
The upstream caspases 2, 8 and 9, and the downstream
caspase 3 were used for the present investigation. Colon
cancer (HT-29) cell line was chosen to investigate the
activity of caspase 2, 3, 8 and 9 after treatment with
compounds 1, 9 and 15 for different treatment times (2, 6
and 24 h). For 2 h treatment it was observed that caspases
2, 3 and 9 were not activated by the substances whereas
activation of caspase 8 was seen in case of compound 9.
The cells treated for 6 h with 15 and 9 seem to show
activation of all caspases—caspase 2, 3, 8 and 9. On the
other hand treatment for 6 h with 1 showed activation of
only caspase 2. The upregulation of caspase 9 was slightly
higher than upregulation of caspase 8 when treated with
compounds 9 and 15 after 6 h. The activation of caspase 2
caused by 15 is much higher than that caused by 1 or 15.
On 24 h treatment with 1, a small upregulation of caspase 3
was observed with no significant activation of other
caspases. On the other hand, treatment for 24 h with 9
and 15 an upregulation and accumulation of caspases 2, 3,
8 and 9 was noted. Activity of caspase 9 subsided but an
increase in caspase 3 upregulation was observed with
compounds 9 and 15 on a 24 h treatment when compared
to 6 h exposure (Fig. 4).
Discussion
This study demonstrates that modification of C-3-
hydroxyl group of betulinic acid with an acetyl moiety
leads to a change in cytotoxicity when compared to
betulinic acid. The change though cannot be generalized,
the compound 3 is more toxic than betulinic acid, 1 on
melanoma (518A2) and lung cancer cell line (A549)
whereas less toxic than betulinic acid in rest of the cell
lines. Conversion of C-28 carboxylic group of betulinic
acid into methyl ester (4) has rendered to less cytotoxic
derivative. The conversion of C-28 carboxylic acid group
of 3-O-acetylbetulinic into a methyl ester, 5 rendered a fall
in toxicity. Moreover, modification of C-28-carboxylic
acid group of compound 3 into long chain alkyl ester (7)
or chloro substituted medium chain alkyl ester (6) yielded
Fig. 3 DNA laddering on
HT-29 colon cancer cell line
induced by 9 and 15
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non toxic derivatives. In contrast, conversion of C-3-
hydroxyl group in betulinic acid with chloro substituted
acetyl group yielded a highly toxic derivative (9). The
compound 9 was found to be 2 to 4 times more cytotoxic
than betulinic acid. Interestingly, 9 was 4 times more
cytotoxic than betulinic acid on HT-29 and 3 times on
A549 cell lines. C-3 substitution with longer chain alkyl
groups (8) has lead to a decrease in cytotoxicity values.
Betulin has a secondary β-hydroxyl group at C-3 and
a primary hydroxyl group at C-28 (see Fig. 1) which can
be easily modified and substituted [19]. Modification of
the inactive betulin with acetyl groups at C-3 and C-28
yielded a moderate to less active derivative 12. Compound
13, C-3-acetylbetulin, showed less to moderate activity
while compound 14, C-28-acetylbetulin, moderate to good
activity on the tumor cell lines used. Derivative 15, C-28-
chloroacetylbetulin, showed better activity than betulinic
acid on the breast (MCF-7) cancer cell line. The
substitution with lauryl group on C-28 position, 10, had
lead to a loss of activity. Modification of both the
hydroxyl groups of betulin with pivaloxymethyl group,
11, rendered a moderately active derivative.
The most active derivatives among the panel of
investigated compounds, 9 and 15, were found to be
selective to tumor cells (Table 2). The compound 9 was
found to be 3.3 times more specific to lung (A549) tumor
cell line compared to human fibroblasts (WWO70327).
Similarly compound 15 was 2 times more selective for
breast (MCF-7) cancer cell line.
The active derivatives 9 and 15 were found to induce
apoptotic cell death on HT-29, colon cancer cell line. This
was proved by dye exclusion (trypan blue) test and DNA
fragmentation assay. To consolidate this caspases 2, 3,
8 and 9 activity on treated colon cancer cell line (HT-29)
cells was investigated. A 2 h treatment with 9 has activated
only caspase 8, whereas a 6 h treatment activated caspases
2, 3, 8 and 9. After 24 h treatment all the caspases were
upregulated. In case of compound 15 no activity of any
caspases at the end of 2 h exposure was observed, while all
the caspases seem to be upregulated with 6 and 24 h
exposure to the compound.
Fig. 4 Activity of caspases 2 (C2), 3(C3), 8(C8) and 9(C9) on HT-29 colon cancer cell line treated for 2, 6 and 24 h with 1, 9 and 15
Table 2 Selectivity indexa of 1, 9 and 15 towards tumor cells
Cell Line 1 9 15
518A2 2.56±0.01 1.22±0.22 1.60±0.35
A549 1.88±0.31 3.38±0.61 1.44±0.33
FaDu 2.04±0.02 1.99±0.45 0.81±0.19
HT-29 1.49±0.05 2.86±0.52 0.57±0.13
MCF-7 1.70±0.01 1.30±0.33 1.94±0.44
a Selectivity index IC50 on human fibrobalsts/IC50 on corresponding
tumor cell line
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Conclusion
Modification of C-3 secondary hydroxyl group into esters
with chloroacetyl side chain (9) yielded a potentially toxic
derivative. Conversion of C-3 secondary hydroxyl group
into methyl ester had lead to an increase in activity in some
cell lines used. Substitution of C-28 carboxylic acid group
of acetyl betulinic acid (3) with short or long chain alkyl
esters results in a fall of activity. Derivatization of C-28
primary hydroxyl group in betulin furnished moderate to
good toxic derivatives. Esterfication of both primary and
secondary hydroxyl groups of betulin gave moderately
active derivatives.
The active derivative 9 was found to induce cell death in
tumor cell line (HT-29) by apoptosis with the involvement
of caspases. Both the compounds 9 and 15 seem to
upregulate caspase 9 significantly, even though a small
activation of caspase 8 was observed. These results may
indicate that compounds 9 and 15 traverse the mitochon-
drial pathway in apoptosis induction. The compounds 9 and
15 seem to show good selectivity towards tumor cell lines
over normal fibroblasts and could be promising agents for
the treatment of human tumors, and are candidates for
further analyses on the experimental animals, in vivo.
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